Traders should monitor upcoming top-line data from the Phase 3 OPERA-01 trial in fall 2026, which will be a key catalyst. While preclinical synergy is encouraging, the lack of clinical data for the OP-3136 combination means near-term upside is limited. Positive data could enhance partnership potential or valuation re-rating.
Price Chart
Executive Summary
Olema Oncology released preclinical data showing palazestrant fully recruits the NCoR1 corepressor for complete estrogen receptor antagonism, and demonstrates synergistic anti-tumor activity when combined with OP-3136 in ER+/HER2- breast cancer models. The data support ongoing Phase 3 trials of palazestrant and the development of OP-3136 in combination therapy, though no clinical efficacy results were reported.
Key Facts
- Preclinical data show palazestrant recruits NCoR1, enabling complete antagonism of estrogen receptor signaling in ER+/HER2- breast cancer models.
- Combination of palazestrant and OP-3136 shows synergistic anti-tumor activity by suppressing cell-cycle and ER-driven oncogenic pathways.
- Palazestrant is in two ongoing Phase 3 trials (OPERA-01 and OPERA-02); top-line data from OPERA-01 expected in fall 2026.
- OP-3136, a KAT6 inhibitor, is in a Phase 1 trial with patient enrollment ongoing.
- Data were presented at AACR 2026, but remain preclinical — no human efficacy or safety results from combinations were disclosed.
Financial Impact
No direct financial impact disclosed; potential long-term value in combination therapy development and differentiation of palazestrant.
Risk Factors
- Preclinical results may not translate to clinical efficacy in humans.
- Delays or negative outcomes in Phase 3 trials (OPERA-01/02) could significantly impact valuation.
- Competitive landscape includes approved SERDs and next-gen endocrine therapies with clinical validation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276477 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 10, 2026 7w ago | Press Release | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 9, 2026 7w ago | Institutional Cluster | $11.94 $10.99 | ▲ +8.00% | ▲ +7.08% | $8.23 (+31.11%) |
May 26, 2026 18w ago | 8-K | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 26, 2026 18w ago | Press Release | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 21, 2026 19w ago | 8-K | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 21, 2026 19w ago | Press Release | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 12, 2026 20w ago | 8-K | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
May 12, 2026 20w ago | Press Release | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
Apr 29, 2026 22w ago | DEFA14A | $14.41 $13.19 | ▼ −8.47% | ▼ −13.69% | $8.23 (−42.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access